Tajikistan

Tajikistan

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
2.52 (2.11 - 2.89) 2019 Modelled IHME
2.62 (2.20 - 3) 2018 Modelled IHME
2.71 (2.24 - 3.15) 2017 Modelled IHME
2.78 (2.28 - 3.19) 2016 Modelled IHME
2.84 (2.30 - 3.27) 2015 Modelled IHME
2.93 (2.37 - 3.35) 2014 Modelled IHME
3.03 (2.44 - 3.47) 2013 Modelled IHME
3.14 (2.53 - 3.60) 2012 Modelled IHME
3.25 (2.63 - 3.74) 2011 Modelled IHME
3.35 (2.72 - 3.87) 2010 Modelled IHME
3.43 (2.82 - 3.97) 2009 Modelled IHME
3.51 (2.89 - 4.07) 2008 Modelled IHME
3.58 (2.96 - 4.15) 2007 Modelled IHME
3.66 (3.05 - 4.24) 2006 Modelled IHME
3.73 (3.11 - 4.36) 2005 Modelled IHME
3.83 (3.18 - 4.43) 2004 Modelled IHME
3.93 (3.26 - 4.54) 2003 Modelled IHME
4.03 (3.31 - 4.66) 2002 Modelled IHME
4.11 (3.37 - 4.76) 2001 Modelled IHME
4.17 (3.41 - 4.83) 2000 Modelled IHME
4.21 (3.44 - 4.89) 1999 Modelled IHME
4.24 (3.45 - 4.95) 1998 Modelled IHME
4.27 (3.49 - 5) 1997 Modelled IHME
4.29 (3.51 - 5.04) 1996 Modelled IHME
4.3 (3.51 - 5.07) 1995 Modelled IHME
4.29 (3.50 - 5.05) 1994 Modelled IHME
4.27 (3.48 - 5.01) 1993 Modelled IHME
4.24 (3.45 - 4.97) 1992 Modelled IHME
4.19 (3.39 - 4.94) 1991 Modelled IHME
4.13 (3.32 - 4.91) 1990 Modelled IHME
5.06 (3.59 - 6.86) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.29 (0.22 - 0.37) 2019 Modelled IHME
0.32 (0.25 - 0.41) 2018 Modelled IHME
0.34 (0.26 - 0.44) 2017 Modelled IHME
0.35 (0.26 - 0.44) 2016 Modelled IHME
0.35 (0.26 - 0.45) 2015 Modelled IHME
0.36 (0.27 - 0.46) 2014 Modelled IHME
0.38 (0.28 - 0.48) 2013 Modelled IHME
0.41 (0.30 - 0.51) 2012 Modelled IHME
0.43 (0.33 - 0.55) 2011 Modelled IHME
0.46 (0.34 - 0.60) 2010 Modelled IHME
0.48 (0.37 - 0.61) 2009 Modelled IHME
0.5 (0.38 - 0.63) 2008 Modelled IHME
0.53 (0.40 - 0.67) 2007 Modelled IHME
0.56 (0.42 - 0.72) 2006 Modelled IHME
0.61 (0.46 - 0.78) 2005 Modelled IHME
0.89 (0.65 - 1.13) 2004 Modelled IHME
1.45 (1.07 - 1.85) 2003 Modelled IHME
2.12 (1.56 - 2.74) 2002 Modelled IHME
2.7 (1.97 - 3.51) 2001 Modelled IHME
2.99 (2.16 - 3.87) 2000 Modelled IHME
3.07 (2.27 - 3.95) 1999 Modelled IHME
3.13 (2.34 - 3.99) 1998 Modelled IHME
3.18 (2.39 - 4.02) 1997 Modelled IHME
3.21 (2.41 - 4.03) 1996 Modelled IHME
3.22 (2.42 - 4.05) 1995 Modelled IHME
3.21 (2.41 - 4.02) 1994 Modelled IHME
3.18 (2.36 - 3.99) 1993 Modelled IHME
3.12 (2.30 - 3.95) 1992 Modelled IHME
3.04 (2.19 - 3.93) 1991 Modelled IHME
2.95 (2.06 - 3.91) 1990 Modelled IHME
0.71 (0.43 - 1.17) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
21 (15 - 27) 2019 Modelled IHME
21 (16 - 27) 2018 Modelled IHME
21 (15 - 27) 2017 Modelled IHME
21 (15 - 27) 2016 Modelled IHME
20 (15 - 26) 2015 Modelled IHME
20 (14 - 26) 2014 Modelled IHME
19 (14 - 26) 2013 Modelled IHME
19 (14 - 26) 2012 Modelled IHME
19 (14 - 26) 2011 Modelled IHME
19 (14 - 25) 2010 Modelled IHME
18 (13 - 25) 2009 Modelled IHME
18 (13 - 24) 2008 Modelled IHME
17 (13 - 23) 2007 Modelled IHME
17 (12 - 23) 2006 Modelled IHME
17 (12 - 23) 2005 Modelled IHME
16 (12 - 22) 2004 Modelled IHME
16 (12 - 23) 2003 Modelled IHME
16 (12 - 22) 2002 Modelled IHME
16 (12 - 22) 2001 Modelled IHME
16 (11 - 22) 2000 Modelled IHME
16 (11 - 22) 1999 Modelled IHME
16 (11 - 22) 1998 Modelled IHME
16 (12 - 22) 1997 Modelled IHME
16 (12 - 22) 1996 Modelled IHME
16 (12 - 22) 1995 Modelled IHME
16 (12 - 22) 1994 Modelled IHME
16 (12 - 22) 1993 Modelled IHME
16 (12 - 22) 1992 Modelled IHME
16 (12 - 22) 1991 Modelled IHME
16 (12 - 21) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
99 2018 Survey/reported WHO/UNICEF
99 2017 Survey/reported WHO/UNICEF
92 2016 Survey/reported WHO/UNICEF
95 2015 Survey/reported WHO/UNICEF
98 2014 Survey/reported WHO/UNICEF
98 2013 Survey/reported WHO/UNICEF
98 2012 Survey/reported WHO/UNICEF
98 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
97 2009 Survey/reported WHO/UNICEF
85 2008 Survey/reported WHO/UNICEF
83 2007 Survey/reported WHO/UNICEF
94 2006 Survey/reported WHO/UNICEF
98 2005 Survey/reported WHO/UNICEF
90 2004 Survey/reported WHO/UNICEF
77 2003 Survey/reported WHO/UNICEF
80 2002 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
96 2018 Survey/reported WHO/UNICEF
96 2017 Survey/reported WHO/UNICEF
97 2016 Survey/reported WHO/UNICEF
96 2015 Survey/reported WHO/UNICEF
97 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
94 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
93 2010 Survey/reported WHO/UNICEF
93 2009 Survey/reported WHO/UNICEF
86 2008 Survey/reported WHO/UNICEF
84 2007 Survey/reported WHO/UNICEF
88 2006 Survey/reported WHO/UNICEF
81 2005 Survey/reported WHO/UNICEF
81 2004 Survey/reported WHO/UNICEF
58 2003 Survey/reported WHO/UNICEF
39 2002 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
278 (188 - 414) 2016 Survey/reported Larney S et al, 2017
HBV elimination goal
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
3.82 (3.08 - 4.70) 2019 Modelled IHME
3.86 (3.12 - 4.79) 2018 Modelled IHME
3.87 (3.11 - 4.81) 2017 Modelled IHME
3.84 (3.12 - 4.72) 2016 Modelled IHME
3.8 (3.07 - 4.67) 2015 Modelled IHME
3.82 (3.10 - 4.70) 2014 Modelled IHME
3.84 (3.12 - 4.73) 2013 Modelled IHME
3.88 (3.13 - 4.79) 2012 Modelled IHME
3.91 (3.14 - 4.80) 2011 Modelled IHME
3.92 (3.15 - 4.83) 2010 Modelled IHME
3.91 (3.15 - 4.77) 2009 Modelled IHME
3.88 (3.13 - 4.74) 2008 Modelled IHME
3.84 (3.11 - 4.71) 2007 Modelled IHME
3.82 (3.07 - 4.71) 2006 Modelled IHME
3.8 (3.04 - 4.72) 2005 Modelled IHME
3.82 (3.05 - 4.73) 2004 Modelled IHME
3.85 (3.09 - 4.76) 2003 Modelled IHME
3.88 (3.14 - 4.79) 2002 Modelled IHME
3.91 (3.16 - 4.84) 2001 Modelled IHME
3.93 (3.17 - 4.87) 2000 Modelled IHME
3.91 (3.15 - 4.81) 1999 Modelled IHME
3.86 (3.12 - 4.76) 1998 Modelled IHME
3.8 (3.08 - 4.68) 1997 Modelled IHME
3.75 (3.04 - 4.60) 1996 Modelled IHME
3.73 (3.03 - 4.60) 1995 Modelled IHME
3.73 (3.04 - 4.58) 1994 Modelled IHME
3.74 (3.04 - 4.59) 1993 Modelled IHME
3.74 (3.05 - 4.61) 1992 Modelled IHME
3.75 (3.06 - 4.60) 1991 Modelled IHME
3.76 (3.04 - 4.63) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
3.1 (1.10 - 6.70) 2014 Modelled Gower et al, 2014
People who inject drugs (PWID)
Download
Value (%) Year Type Source
61.3 (56.80 - 65.60) 2004 Survey/reported Beyrer C et al, 2009

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
45 (36 - 53) 2019 Modelled IHME
46 (37 - 54) 2018 Modelled IHME
46 (37 - 54) 2017 Modelled IHME
46 (37 - 54) 2016 Modelled IHME
46 (38 - 55) 2015 Modelled IHME
47 (38 - 55) 2014 Modelled IHME
46 (37 - 55) 2013 Modelled IHME
46 (37 - 55) 2012 Modelled IHME
46 (37 - 55) 2011 Modelled IHME
46 (37 - 55) 2010 Modelled IHME
46 (37 - 54) 2009 Modelled IHME
46 (37 - 54) 2008 Modelled IHME
46 (37 - 55) 2007 Modelled IHME
46 (37 - 55) 2006 Modelled IHME
46 (38 - 55) 2005 Modelled IHME
46 (37 - 54) 2004 Modelled IHME
46 (37 - 54) 2003 Modelled IHME
46 (37 - 54) 2002 Modelled IHME
45 (37 - 53) 2001 Modelled IHME
45 (36 - 52) 2000 Modelled IHME
44 (36 - 51) 1999 Modelled IHME
43 (35 - 51) 1998 Modelled IHME
42 (34 - 50) 1997 Modelled IHME
41 (33 - 48) 1996 Modelled IHME
40 (32 - 48) 1995 Modelled IHME
41 (33 - 48) 1994 Modelled IHME
42 (34 - 50) 1993 Modelled IHME
42 (33 - 50) 1992 Modelled IHME
42 (33 - 50) 1991 Modelled IHME
42 (34 - 49) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (188 - 414) 2016 Survey/reported Larney S et al, 2017
HBV elimination goal
HBV National Action Plan
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
No
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
Yes
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Most (61-100%)
% of substance use disorder facilities offering hepatitis treatment
None

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
2.52 (%)
2019
(2.11 - 2.89(%))
IHME
HCV (RNA/cAg+)
3.82 (%)
2019
(3.08 - 4.7(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
445
2019
(313 - 615)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
574
2019
(409 - 787)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.29 (%)
2019, latest modelled
(0.22 - 0.37(%))
IHME

Prevalence PWID

HCV
0
, latest modelled

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
99 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
278
2016
(188 - 414)
Larney S et al, 2017
Eligible for HBV generic medicines
Eligible for HCV generic medicines